CCKAR and serum lipopolysaccharide activity: As a key factor in the P38 pathway, CCKAR inhibits the release of inflammatory factors and thus inhibits the process of inflammation.[30,31] In addition, CCKAR has also been demonstrated to be beneficial in reducing TNF absorption and attenuating gut mediator-induced lung damage during endotoxemia.[32] This is consistent with the result of our study that CCAKR is negatively correlated with TNF which is a key factor of ALI,[33] however, its mechanism remains to be studied.